Physician profile
Jeffrey C Acker
NPI 1013916543
$4,424.10
in general payments reported to CMS, 2019-2025
37 companies · $700 in 2025
The $700 reported for 2025 was more than what 79% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $264 · 2021: $132 · 2022: $541 · 2023: $807 · 2024: $715 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,222.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $514.85 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $316.47 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $269.75 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $252.73 | 2019-2025 | Enhertu |
| Seagen INC. | $229.37 | 2021-2023 | Padcev, Adcetris, Tukysa |
| Elekta, INC. | $221.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $200.94 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Eisai INC. | $187.14 | 2022-2025 | |
| Genentech USA, INC. | $176.99 | 2019-2025 | Tecentriq, Alecensa, Rozlytrek |
| Bayer Healthcare Pharmaceuticals INC. | $159.62 | 2019-2025 | |
| Incyte Corporation | $155.25 | 2022-2025 | Monjuvi, Pemazyre |
| Lilly USA, LLC | $144.86 | 2019-2024 | Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $125.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $124.98 | 2022-2025 | |
| Zap Surgical Systems, INC. | $120.51 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $116.64 | 2023-2025 | |
| Accuray Incorporated | $112.22 | 2019 | |
| Siemens Medical Solutions USA, INC. | $109.67 | 2021-2025 | Truebeam |
| Regeneron Healthcare Solutions, INC. | $107.20 | 2023-2025 | Libtayo |
| Amgen INC. | $104.67 | 2022-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $95.77 | 2019-2024 | Tagrisso |
| Celgene Corporation | $92.86 | 2019-2022 | |
| Pfizer INC. | $88.19 | 2024-2025 | |
| Exelixis INC. | $78.08 | 2021-2024 | Cabometyx |
| Teleflex LLC | $62.08 | 2024-2025 | Barrigel |
| Aveo Pharmaceuticals, INC. | $41.44 | 2024-2025 | |
| Abiomed | $28.90 | 2024 | Impella |
| Myovant Sciences INC. | $27.08 | 2022 | |
| Sobi, INC | $25.32 | 2025 | |
| Menarini Silicon Biosystems, INC. | $23.20 | 2025 | Cellsearch |
| Progenics Pharmaceuticals, INC. | $22.89 | 2022 | |
| Beigene USA, INC. | $22.69 | 2023 | Brukinsa |
| Janssen Biotech, INC. | $20.58 | 2024 | Rybrevant |
| Brainlab, INC. | $16.00 | 2019 | |
| Boston Scientific Corporation | $14.55 | 2020 | |
| Heron Therapeutics, INC. | $12.06 | 2020 | |
| Forte Bio-Pharma LLC | $2.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.